Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland

[1]  C. Porta,et al.  Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma , 2022, Cancer.

[2]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. , 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  G. De Velasco,et al.  ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Joe Y. Chang,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  F. Ejzykowicz,et al.  PDG5 Updated Lifetime Survival Estimates for Nivolumab+ipilimumab in Previously Untreated Advanced/Metastatic Intermediate- or Poor-Risk Renal Cell Carcinoma (1L aRCC) , 2020 .

[8]  S. Ho,et al.  PCN42 Real-World Effectiveness in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma – a Systematic Literature Review Update , 2020 .

[9]  T. Powles,et al.  Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[10]  M. Atkins,et al.  713P Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214 , 2020 .

[11]  C. Porta,et al.  Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial , 2020, Journal for ImmunoTherapy of Cancer.

[12]  B. Malcolm,et al.  PCN421 STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA , 2019, Value in Health.

[13]  B. Malcolm,et al.  PCN140 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND , 2019, Value in Health.

[14]  Chongqing Tan,et al.  First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis , 2019, JAMA oncology.

[15]  A. Bonetti,et al.  Cost‐Effectiveness of Second‐Line Treatments for Metastatic Renal‐Cell Carcinoma , 2019, Clinical genitourinary cancer.

[16]  Q. Zhang,et al.  Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma , 2018, Journal of Immunotherapy for Cancer.

[17]  M. Leshno,et al.  A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma. , 2019, The oncologist.

[18]  F. Stenner,et al.  Pattern of Care Study in Metastatic Renal‐Cell Carcinoma in the Preimmunotherapy Era in Switzerland , 2018, Clinical genitourinary cancer.

[19]  A. Bonetti,et al.  Nivolumab Is a Cost‐Effective Second‐Line Treatment for Metastatic Renal‐Cell Carcinoma , 2018, Clinical genitourinary cancer.

[20]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[21]  K. Bensalah,et al.  Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. , 2017, European urology.

[22]  M. Uysal,et al.  Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients? , 2015, Clinical genitourinary cancer.

[23]  A. Poprach,et al.  Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study , 2015, Targeted Oncology.

[24]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[25]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[26]  Gérard de Pouvourville,et al.  Valuing EQ-5D using Time Trade-Off in France , 2013, The European Journal of Health Economics.

[27]  Nicholas R Latimer,et al.  Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  Lorenzo Marconi,et al.  EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.

[29]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Chow,et al.  Contemporary Epidemiology of Renal Cell Cancer , 2008, Cancer journal.

[31]  C. Charbonneau,et al.  Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.

[32]  W. Greiner,et al.  Validating the EQ-5D with time trade off for the German population , 2005, The European Journal of Health Economics.

[33]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[34]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[35]  F. Dubois-Arber,et al.  Short appraisal of the role and usefulness of drug consumption facilities (DCF) in the reduction of drug-related problems in Switzerland : appaisal produced at the request of the Swiss Federal Office of Public Health , 2004 .